Seres Therapeutics (MCRB) Misses Q4 EPS by 61c

Seres Therapeutics (NASDAQ: MCRB) reported Q4 EPS of ($0.81), $0.61 worse than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• H.C. Wainwright Starts Seres Therapeutics (MCRB) at Buy
• Active options: MSFT PLTR META GOOGL SOFI MSTR IREN AMC IBM SMCI HOOD AMD
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance